Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Current Assets (2016 - 2025)

Historic Current Assets for Ascendis Pharma A (ASND) over the last 14 years, with Q3 2025 value amounting to $1.2 billion.

  • Ascendis Pharma A's Current Assets rose 1126.46% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 1126.46%. This contributed to the annual value of $1.1 billion for FY2024, which is 5186.25% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Current Assets of $1.2 billion as of Q3 2025, which was up 1126.46% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Current Assets ranged from a high of $1.3 billion in Q1 2022 and a low of $675.6 million during Q2 2024
  • Moreover, its 5-year median value for Current Assets was $942.2 million (2022), whereas its average is $943.7 million.
  • Per our database at Business Quant, Ascendis Pharma A's Current Assets soared by 317186.63% in 2021 and then tumbled by 3781.41% in 2023.
  • Over the past 5 years, Ascendis Pharma A's Current Assets (Quarter) stood at $794.8 million in 2021, then increased by 18.55% to $942.2 million in 2022, then decreased by 19.75% to $756.1 million in 2023, then skyrocketed by 49.93% to $1.1 billion in 2024, then increased by 4.96% to $1.2 billion in 2025.
  • Its Current Assets stands at $1.2 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $969.3 million for Q1 2025.